Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury‘s companies to watch within the macrocycle chemistry space.
The reference came in Chris Cain‘s article, “Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals.”
This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program.
The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research.
BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.
A French version of this release is available via CQDM’s website.
This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to increase innovation, productivity, investment and job creation.
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca